Publications

Nov 01, 2021 A prospective observational study for justification, safety, and efficacy of a third dose of mRNA vaccine in patients receiving maintenance hemodialysis

by M.Espi, X.Charmetant (...) and O.Thaunat, Kidney International 2021, DOI : 10.1016/j.kint.2021.10.040

Experience from five Asia-Pacific countries during the first wave of the COVID-19 pandemic: Mitigation strategies and epidemiology outcomes

Travel Med Infect Dis.

Sep 14, 2021 Nature communications : last LYACTS team publication

Sep 08, 2021 The ROMANOV study found impaired humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in virus-unexposed patients receiving maintenance hemodialysis

Espi M, Charmetant X, et al, Kid Int 2021

Aug 09, 2021 JEM, 2021, August 06 :Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

Evidence for long-term association of virion-delivered Hepatitis B virus Core protein with cccDNA independently of viral protein production

Lucifora, Pastor et al., JHep Reports, 2021 / Team HepVir

Jul 07, 2021 A breath of humanity in the era of Covid-19 vaccine

Jun 24, 2021 Nipah virus W protein harnesses nuclear 14-3-3 to inhibit NF-κB-induced proinflammatory response

ALPK1 gene mutations drive autoinflammation with ectodermal dysplasia and progressive vision loss

ALPK1 is a kinase sensing a bacterial metabolite from the LPS biosynthesis pathway. Our favorite clinician describes a new family of patients. This rare monogenic disease associated with vision loss is still poorly known in the field of autoinflammation and this description of a new family of patients should raise awareness on the inflammatory symptoms associated with this disease.

Science Translational Medicine: UBIVE publication on Lassa fever vaccine

May 25, 2021 Science Immunology : LYACTS team publication on MIS-C syndrome

May 09, 2021 The Journal of Immunology : last publication LYACTS team

Communications - Congress

New contribution in the field of Covid-19 research

Sections

Managing bodies

Secondary managing bodies

Contact